Gastric cancer that mimics a submucosal tumor is rare. This rarity and the normal mucosa covering the protuberant tumor make it difficult to diagnosis with endoscopy. We report two cases of advanced gastric cancer that mimicked malignant gastrointestinal stromal tumors preoperatively. In both cases, the possibility of cancer was not completely ruled out. In the first case, a large tumor was suspected to be cancerous during surgery. Therefore, total gastrectomy with lymph node dissection was performed. In the second case, the first gross endoscopic finding was of a Borrmann type II advanced gastric cancer-like protruding mass with two ulcerous lesions invading the anterior wall of the body. Therefore, subtotal gastrectomy with lymph node dissection was performed. Consequently, delayed treatment of cancer was avoided in both cases. If differential diagnosis between malignant gastrointestinal stromal tumor and cancer is uncertain, a surgical approach should be carefully considered due to the possible risk of adenocarcinoma.
Introduction
Gastric cancer that mimics a submucosal tumor (SMT) is rare, with a reported incidence of 0.1% to 0.63%. 1 As the surface of the tumor is covered with mucosa that appears normal, it is difficult to obtain an adequate specimen from the underlying lesion. However, the differential diagnosis between a mesenchymal tumor, malignant lymphoma, and a carcinoid tumor is important to determine the optimal treatment strategy. In the treatment of locally advanced or borderline resectable gastrointestinal stromal tumors (GISTs), neoadjuvant imatinib has frequently resulted in regression or stabilization of the tumor. In addition, due to the rarity of lymphatic metastases in GIST, regional lymph node dissection is not performed.
Herein, we report two cases of advanced gastric cancer (AGC) that mimicked malignant GIST and that were treated with palliative total gastrectomy and laparoscopy-assisted distal gastrectomy, respectively.
Case Report 
Case 2
A 68-year-old man was referred to our hospital in January 2011
for differential diagnosis between AGC and malignant SMT. The tumor was mostly located within the submucosa and the muscle layer, with a very focal mucosal lesion. A deep infiltrating gland showed intraluminal mucin and an extracellular mucin pool in the subserosal layer (Fig. 4) . The tumor was a mucinous carcinoma without metastasis to regional lymph nodes (N0 stage). The final diagnosis was of advanced gastric carcinoma without regional lymph node metastasis. The patient was discharged without any post-operative complications.
The patient underwent chemotherapy with TS-1 immediately after recovering from surgery. A CT scan taken 6 months after surgery showed no evidence of recurrence or metastasis. There has been no evidence of local recurrence in the follow-up CT scans and upper gastrointestinal endoscopy examinations at 6-month intervals up to the last follow-up in July 2014. The patient has been in good general condition after discharge.
Discussion
Most gastric cancers are epithelial neoplasms that can be diagnosed by routine endoscopic biopsy. However, a gastric adenocarcinoma covered with normal-looking mucosa can macroscopically mimic a SMT on rare incidence (0.1%~0.63%). 2 This rarity and the normal mucosa covering the protuberant tumor make it difficult to confirm diagnosis with endoscopy. Furthermore, this distinction is crucial in terms of therapeutic strategy. Treatment options for GIST include surgery and imatinib mesylate (Gleevec; Novartis, Basel, Switzerland), a competitive inhibitor of tyrosine kinases such as BCR-ABL, ARG, KIT, PDGFRa, and PDGFRb. 3, 4 Complete surgical resection is the most important factor with respect to survival in the treatment of GIST. 5 However, routine lymph node dissection is unnecessary because lymphatic spread of GIST is very uncommon. 6 In contrast, for all resectable T1b~T4 gastric cancers, optimal lymphadenectomy (D2 dissection) should be recommended as a standard of care. 7 Large SMTs carry an increased risk of rupture, which has an unfavorable effect on disease-free and overall survival. 8 Furthermore, according to a recent report, nearly all patients develop abdominal metastases following rupture of a GIST. 9 However, imatinib induction therapy to reduce the size of large tumors could potentially reduce the risk of tumor rupture during surgery and provide an opportunity for a surgically complete and less morbid resection. 10 Therefore, imatinib could be the first therapeutic option for large GISTs. However, imatinib is contraindicated for submucosal gastric cancer because it has no clinical effect on cancer and delays the diagnosis and treatment of cancer.
In the first case presented here, a large protuberant tumor was diagnosed as malignant SMT by radiological findings, and was diagnosed as chronic active gastritis with intestinal metaplasia twice by double-checked upper gastrointestinal endoscopic biopsy.
However, prompt surgical intervention was performed because the possibility of gastric cancer had not been completely ruled out. We suspected the tumor to be gastric cancer during surgery. Therefore, total gastrectomy with lymph node dissection was performed.
In the second case, although the results of double-checked endoscopic biopsies indicated chronic active gastritis with intestinal metaplasia, the possibility of cancer was not completely ruled out, because the first gross endoscopic finding was a Borrmann type II AGC-like protruding mass. Furthermore, the large tumor with two ulcerous lesions invaded the entire anterior wall of the body of the stomach without serosal invasion. Additionally, the indication of laparoscopic gastrectomy for gastric cancer in our institute is T1N0, T1N1, and T2N0. Therefore, laparoscopic subtotal gastrectomy with lymph node dissection was performed.
In both cases, simple endoscopic biopsy was performed twice to aid the differential diagnosis. Unfortunately, the endoscopist in our institution did not perform a deep biopsy because of worries about perforation, bleeding, and delayed diagnosis. Therefore, the patient and their family were asked for informed consent prior to the operation because of the possibility of gastric cancer and SMT prior to operation.
Consequently, delayed treatment of cancer was avoided in both cases. If differential diagnosis between malignant GIST and cancer is uncertain, a surgical approach should be carefully considered due to the possible risk of adenocarcinoma.
